ArticleMolecules (Basel, Switzerland)2026
Searching for Metabolic Markers for Hypertension in Human Urine.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hypertension is a leading risk factor for the development of cardiovascular diseases and is associated with higher morbidity and mortality rates. However, hypertension screening is not routinely applied to asymptomatic individuals and can be influenced by several factors, such as adequate technique and patient emotional factors, recent exercise, and oral consumptions. Therefore, in this study, we aimed to analyze the urinary metabolomic profiles in normotensive and hypertensive participants by untargeted NMR to identify novel biomarkers for hypertension in a population with a high prevalence of hypertension. Hypertensive participants (when compared with normotensive participants) without cardiovascular or metabolic comorbidities had higher urinary levels of sarcosine and lower levels of acetone, citrate, 4-hydroxyphenylacetate, 3-methylglutaconate, N-isovaleroylglycine, oxaloacetate, phenylalanine and pyridoxate. These metabolites are involved in energy metabolism, amino acid metabolism, gut microbiota-derived metabolism, and vitamin B6 metabolism, reinforcing previous evidence of metabolic changes in hypertension. None of the metabolites were significantly influenced by the presence of cardiovascular or metabolic comorbidities such as dyslipidemia, diabetes, or other cardiovascular diseases, supporting their association with hypertension. To our knowledge, this is the first study to report changes in urinary acetone, oxaloacetate, 3-methylglutaconate, N-isovaleroylglycine and pyridoxate in hypertensive individuals (vs. normotensive individuals). Citrate, methylglutaconate, N-isovaleroylglycine, oxaloacetate, phenylalanine and sarcosine seem to have a higher potential for reliable hypertension biomarkers, since they were also not significantly influenced by any of the anti-hypertensive treatments. Together, these findings expand the current urinary metabolomic profile of hypertension and highlight the potential of these urinary metabolites as a non-invasive approach for earlier hypertension detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.